Drug Profile

REX 8756

Alternative Names: REX-8756

Latest Information Update: 07 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Recludix Pharma
Class Anti-inflammatories; Antiasthmatics; Skin disorder therapies; Small molecules
Mechanism of Action STAT6 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease

Most Recent Events

14 Jun 2025 Recludix Pharma and Sanofi agree to co-develop STAT6 transcription factor inhibitors for multiple immunological and inflammatory indications
02 Jun 2025 Preclinical trials in Asthma in USA (PO), before June 2025
02 Jun 2025 Preclinical trials in Atopic dermatitis in USA (PO), before June 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com